Please ensure Javascript is enabled for purposes of website accessibility
Skip to main content
Poised to address unmet need in neuromuscular diseases and
positioned for growth

Press Releases

Press Releases

2026 2025 2024 2023 2022 2021 2020 2019 all

March 8, 2026

Dyne Therapeutics Announces Initiation of Phase 3 HARMONIA Trial of Z-Basivarsen in Myotonic Dystrophy Type 1 (DM1)

March 8, 2026

Dyne Therapeutics Announces New Positive Cardiopulmonary Results from DELIVER Trial of Z-Rostudirsen in Duchenne Muscular Dystrophy (DMD)

March 2, 2026

Dyne Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights

February 25, 2026

Dyne Therapeutics to Participate in Upcoming Investor Conferences

February 22, 2026

Dyne Therapeutics Announces Upcoming Presentations Across Neuromuscular Pipeline at 2026 MDA Clinical & Scientific Conference

January 20, 2026

Dyne Therapeutics Receives Orphan Drug Designation in Japan for Zeleciment Basivarsen (DYNE-101) for Myotonic Dystrophy Type 1

January 7, 2026

Dyne Therapeutics to Present at 44th Annual J.P. Morgan Healthcare Conference

December 23, 2025

Dyne Therapeutics Appoints Vikram Karnani to Board of Directors

December 11, 2025

Dyne Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares

December 9, 2025

Dyne Therapeutics Announces Pricing of Upsized $350.0 Million Public Offering of Common Stock

December 8, 2025

Dyne Therapeutics Announces Proposed Public Offering of Common Stock

December 8, 2025

Dyne Therapeutics Announces Positive Topline Results from Phase 1/2 DELIVER Trial of Z-Rostudirsen in Duchenne Muscular Dystrophy (DMD)

December 7, 2025

Dyne Therapeutics to Host Investor Conference Call and Webcast to Review Topline Results from Registrational Expansion Cohort (REC) of DELIVER Clinical Trial of Z-Rostudirsen (DYNE-251) in Duchenne Muscular Dystrophy; Tomorrow, December 8 at 8:00 a.m. ET

November 5, 2025

Dyne Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights

November 3, 2025

Dyne Therapeutics to Present at Upcoming Investor Conferences

October 6, 2025

Dyne Therapeutics Announces Additional One-Year Clinical Data Demonstrating Functional Improvement from Phase 1/2 ACHIEVE Trial of Zeleciment Basivarsen (DYNE-101) for Myotonic Dystrophy Type 1 (DM1)

October 2, 2025

Dyne Therapeutics Appoints Brian Posner to its Board of Directors

September 29, 2025

Dyne Therapeutics Receives Orphan Drug Designation in Japan for DYNE-251 in Duchenne Muscular Dystrophy

August 27, 2025

Dyne Therapeutics to Present at Upcoming Investor Conferences

August 4, 2025

Dyne Therapeutics Announces FDA Breakthrough Therapy Designation for DYNE-251 in Duchenne Muscular Dystrophy (DMD)
Displaying 1 - 20 of 153
Stay in touch

You are now leaving 
the Dyne Therapeutics corporate website

Continue